BIOWEG plans to start construction of a bacterial cellulose production plant in Elsdorf, North Rhine-Westphalia, during the fourth quarter of 2026, taking the German biotechnology company from pilot manufacture towards its first large industrial facility.
BIOWEG says the plant will ultimately provide capacity of up to 10,000 tonnes a year for biodegradable ingredients intended to replace fossil-derived polymers and intentionally added microplastics. First commercial volumes are targeted for 2028, with around 60% of the company’s accumulated funding allocated to the Elsdorf project.
The latest company figure is higher than the capacity currently recorded in North Rhine-Westphalia’s public project database. That register describes a first-of-a-kind fermentation facility producing approximately 5,000 tonnes a year of RheoWeg and 50 tonnes of micropowder. The available material does not reconcile the two figures, so the 10,000-tonne number remains BIOWEG’s stated current design capacity rather than an independently confirmed output figure.
The project is supported by a financing package that BIOWEG says has reached €35 million in total. This includes €18 million in equity following a further €2 million investment from Rabo Ventures, €10.3 million in non-dilutive support through the Produktives.NRW grant competition, and additional funding from other sources.
The regional project register independently records a funding framework of €10.2656 million and a project period running from June 2026 to March 2029. It describes the facility as a first-of-a-kind biomanufacturing operation using waste and residual streams to produce biodegradable materials.
Bacterial cellulose is produced by microorganisms through fermentation rather than being extracted directly from plants. BIOWEG processes the resulting material into functional ingredients for applications including agricultural coatings, cosmetics, personal care, home care, and formulations in which conventional synthetic polymers provide rheology, suspension, film-forming, or processing functions.
Dr Prateek Mahalwar, co-founder and chief executive of BIOWEG, said: “Food and agricultural side streams will always be available locally in Europe, and Elsdorf is where we’ll turn them into high-performance, biodegradable ingredients at industrial scale.”
The plant will be built within a large German sugar-industry complex, allowing BIOWEG to use molasses and other local side streams as fermentation feedstock. Locating close to that material source reduces transport and gives the process access to a predictable carbohydrate stream that would otherwise have to be purchased and moved over greater distances.
Feedstock is only one part of fermentation economics, but it can be a significant one. Industrial biotechnology plants also depend on yield, productivity, utilities, contamination control, downstream separation, drying or finishing, plant utilisation, and the amount of saleable material recovered from each batch.
BIOWEG intends the new facility to be highly automated, drawing on operating practices from the surrounding sugar industry. Large fermentation processes require consistent control of temperature, aeration, nutrients, process timing, harvesting, and downstream treatment, while biological contamination or lost batches can quickly erode the economics of a plant operating on commodity-scale margins.
The company’s existing Quakenbrück pilot site will remain in operation during construction. BIOWEG says it is upgrading that facility from around 100 tonnes to at least 200 tonnes of annual capacity and introducing further automation, allowing it to supply commercial batches through 2027 and 2028 while using the smaller operation as a process blueprint for Elsdorf.
The commercial opportunity is being helped by regulation. The European restriction on intentionally added synthetic polymer microparticles under REACH is being introduced across different applications on phased timetables, forcing formulators to assess alternative materials where synthetic microplastics have historically provided a useful technical function.
Regulatory pressure creates a reason to reformulate but does not remove the normal purchasing constraints. Manufacturers still require materials that perform consistently, remain available in industrial quantities, run through existing processes, and produce an acceptable cost per finished product.
BIOWEG says its agricultural ingredients can deliver required functions at up to 70% lower dosage than conventional synthetic alternatives in some formulations. That is a manufacturer performance claim and will depend on the application, but it illustrates why dosage matters: a more expensive material can still produce competitive cost-in-use if substantially less is needed.
Elsdorf is also part of the Rheinische Revier, where public investment is being used to attract new industries as the region moves away from coal-related activity. BIOWEG expects around 30 high-technology jobs at the site, a comparatively small employment number beside traditional heavy industry but one tied to a new process-manufacturing capability.
The project now has finance, a location, public backing, and a construction timetable. What it does not yet have is an operating industrial plant, and first-of-a-kind biotechnology facilities earn credibility through stable yields, repeatable product quality, and customer qualification rather than projected nameplate capacity. Elsdorf will start answering those questions when construction begins and the process moves from hundreds of tonnes at Quakenbrück towards genuinely industrial volumes.
